Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent

Depressive Disorder, Major Clinical Trial

— ISORADAR  

Official title:

Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent in Treatment Resistant Depression Patients : Proof of Concept

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04171193
• Other study ID #: ISORADAR
• Secondary ID: 19921719.9.0000.
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 2019
• Est. completion date: December 2020

Study information

• Verified date: November 2019
• Source: University of Sao Paulo
• Contact: Tiago Gil, MD
• Phone: 5511983817707
• Email: Tiagogil[@]gmail.colm
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study the investigators will submit patients with treatment resistant depression to deep anesthesia with isoflurane to get 15 minutes of cortical burst suppression on electroencephalogram, once a week for six weeks. The follow up will be for 6 months. The aim is to evaluate the change in depression severity during the entire period.

Description:

This study protocol will measure the efficacy of deep anesthesia, until burst suppression rate of 80% or more measured with Bi-spectral Index (BIS), with the volatile anesthetic Isoflurane. The investigators will select 30 subjects. The participants will be separated into 2 arms of 15 individuals. One arm called ISOAD will keep the oral treatment with antidepressants. The second arm, called ISO, will do a washout of any oral medications for depression. Both groups will go under six sessions, once per week, of deep anesthesia and will be followed up for 6 months to evaluate the survival of the antidepressant effect, if any effect happens. Before the anesthesia occurs, blood samples will be drawn to measure Brain-derived neurotrophic factor and investigators will apply depression rating scales such as MADRS and Hamilton - 17 , Young mania Scale, UKU scale for side effects, electroencephalogram will be recorder to be compared with the data shown on BIS. All the anesthesia procedure will be done with induction with propofol, fentanyl and muscular relaxant, to facilitate the tracheal intubation and compliance with the mechanical ventilator,based on body weight in standard dosages. Isoflurane will be set to 2,4% ( 2 cam) until Burst suppression rate >80% is achieve. Then the anesthesia will be maintained for 15 minutes, then the flow of anesthetic gas will be ended and the patient will be allowed to awake and discharged home when the anesthesiologist decide based on Aldrete Kroulik scale. After the 6th session the participant will return in one week to final evaluation. All the patients that shows improvement in depression scores will enter the phase 2 with one visit every 15 days for 2 months and then once a month until the 6th month. The non responders of the ISO group will start oral antidepressant sertraline to evaluate any potentialization effect of the intervention and be allocated in ISOPOT group. Those from ISOAD group (Isoflurane plus oral antidepressants) that did not respond to the intervention will be discontinued from the study and their data used in the study as non-responders. Those from ISOPOT group that did not improve their depression scores after 4 weeks will be discontinued from the study and the data computed as non-responders.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 2020
• Est. primary completion date: September 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients with Treatment resistant depression on depressive state with or without psychiatric comorbidities for anxious features

• moderate to severe condition measured by Montgomery Asperger Depression Rating Scale and Hamilton Depression rating scale - 17

• be between 18 and 60 years old

• IF female, do not be pregnant and use a trustable contraceptive method

• can read and write in Portuguese language

• will to be in all the phases of the study

• have agreed with free will to participate

• classified as American Society of Anesthesiologists - Physical Status 1 or 2 by a certified anesthesiologist

• Suicide ideation measured by Montgomery Asperger Depression Rating Scale on item 10 less than 4

Exclusion Criteria:

• drug abusers in the last 6 months, except for nicotine

• use of benzodiazepines or lamotrigine less then 15 days from the first session

• family history of malignant hyperthermia Suicidal ideation on item 10 of Montgomery Asperger Depression Rating Scale more than 4

• Suicide attempt one month prior the study begins

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Depressive Disorder, Treatment-Resistant
• Depressive Episode
• Treatment Resistant Depression

Intervention

Drug:
• Isoflurane
Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
• Sertraline Pill
Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane

Locations

Country	Name	City	State
Brazil	Insitute of Psychiatry of the University of São Paulo	São Paulo

Sponsors (2)

Lead Sponsor	Collaborator
University of Sao Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in Depression severity - MADRS	Any reduction in Montgomery Asperger Depression Rating Scale ( 0 to 60 , lower score means less depression severity)	Six days after the last session
Primary	Reduction in Depression - HDRS 17	Any reduction in Hamilton Depression rating scale 17 ( 0 to 49, lower score means less depression severity	Six days after the last session
Secondary	Udvalg for Kliniske Undersøgelser - side effects rating scale	Development and tolerability of collateral effects using the Udvalg for Kliniske Undersøgelser - side effects rating scale ( 0 to 43 - lower score means less side effects)	From 6th day after the first intervention up to week 24th
Secondary	Change in Depression severity MADRS	Any change in Montgomery Asperger depression ratings scale ( 0 to 60 , lower score means less depression severity)	From 6th day after the intervention up to week 24th
Secondary	Change in Depression severity HDRS17	Any change in Hamilton depression ratings scale 17 ( 0 to 49, lower score means less depression severity)	From 6th day after the intervention up to week 24th
Secondary	Magnitude MADRS	The amount of the reduction, if any, in Montgomery Asperger Depression Rating Scale ( 0 to 60 , lower score means less depression severity)	From 6th day after the intervention up to week 24th
Secondary	Magnitude HDRS 17	The amount of the reduction, if any, in Hamilton Depression rating scale 17 ( 0 to 49, lower score means less depression severity)	From 6th day after the intervention up to week 24th
Secondary	Survival of the effect - HDRS 17	For how long the Hamilton Depression rating scale 17 remains below the initial value (lower value means less depression) in each participant that had variation in this scale	After the 6th session through 24th week
Secondary	Survival of the effect - MADRS	For how long the Montgomery Asperger Depression Rating Scale remains below the initial value (lower value means less depression) in each participant that had variation in this scale	After the 6th session through 24th week
Secondary	Enhance HDRS 17	The magnitude, if any, of the change in Hamilton Depression rating scale 17 measured in patients that did not achieve any primary outcome in the first phase of the study after started sertraline as oral antidepressant.	After the 10th visit through the 24th week
Secondary	Enhance MADRS	The magnitude, if any, of the change in Montgomery Asperger Depression Rating Scale measured in patients that did not achieve any primary outcome in the first phase of the study after started sertraline as oral antidepressant.	After the 10th visit through the 24th week